- $1.87m
- -$1.27m
- $2.49m
Brief: GeoVax Announces Initiation Of Phase 2 Clinical Trial Of COVID-19 Vaccine Booster In Patients With Chronic Lymphocytic Leukemia
Brief: Geovax Partners With ABL To Advance Cgmp Production Of Vaccine Candidates
GeoVax Labs rises on COVID vaccine data
Brief: Geovax's Next-Generation Covid-19 Vaccine Shows High Immunogenicity In Immunocompromised Patients
GeoVax Labs Inc expected to post a loss of 20 cents a share - Earnings Preview
GeoVax Labs Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Geovax Announces Expansion Of Next-Generation Covid-19 Vaccine Rights To Include Omicron Variants
Brief: Geovax Announces Presentation Of Prelim Data From Trial Of Covid-19 Vaccine Candidate
GeoVax Labs Inc reports results for the quarter ended in December - Earnings Summary
GeoVax Labs Inc expected to post a loss of 20 cents a share - Earnings Preview
GeoVax Labs Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Geovax Labs Presents Results From A Clinical Study Of A Combinational HIV Therapy
Brief: GeoVax Announces Decisive Progress In Establishing High-Capacity, Continuous Cell Line System To Manufacture MVA-Based Vaccines
Brief: GeoVax Labs Inc - On December 9, Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement - Filing
GeoVax Labs Inc reports results for the quarter ended in September - Earnings Summary
Brief: Geovax Reports 2022 Third Quarter Financial Results
GeoVax Labs Inc expected to post a loss of 12 cents a share - Earnings Preview
GeoVax Labs rises as H.C. Wainwright initiates with 'buy'
Brief: GeoVax Announces Addition To Its Board Of Directors